BioSpace News Archive

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”) and liver disease, today announced additional efficacy data from its Phase 2a AMBITION clinical trial.

Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), today announced that Dr. John Kellum, Spectral’s Chief Medical Officer, has been recognized as a World Expert in Sepsis by Expertscape.

Sema4 today announced the appointment of Gustavo Stolovitzky , PhD, to the newly established senior leadership position of Chief Science Officer (CSO).

OncoHost, a global leader in next-generation precision oncology for improved personalized cancer therapy, has published a study identifying a predictive proteomic signature for patient response to immune checkpoint inhibitor (ICI) therapy in non-small-cell lung carcinoma (NSCLC) patients.

Silverback Therapeutics, Inc. today announced that interim data from the dose-escalation portion of its Phase 1/1b clinical trial evaluating SBT6050 will be presented at the upcoming European Society for Medical Oncology (ESMO) 2021 Congress from September 16-21, 2021.

Vertex to Present at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference on September 15th

Lineage Cell Therapeutics, Inc. reported that updated interim results from a Phase 1/2a study of its lead product candidate, OpRegen®, a retinal pigment epithelium cell transplant therapy currently in development for the treatment of dry age-related macular degeneration, will be featured in a podium presentation at the 54th Annual Scientific Meeting of the Retina Society, to be held at the Ritz-Carlton Hotel in Chicago, IL.

Apollo Endosurgery, Inc. today announced that its management team will participate in Lake Street’s 5th Annual Best Ideas Growth Conference. September 14-15, 2021

Bristol Myers Squibb today announced three-year data from the CheckMate -743 trial that demonstrated a durable survival benefit with first-line treatment with Opdivo (nivolumab) plus Yervoy (ipilimumab) compared to platinum-based standard-of-care chemotherapy in patients with unresectable malignant pleural mesothelioma (MPM), regardless of histology.

Spectrum Pharmaceuticals today announced a late-breaking presentation of early poziotinib efficacy and safety data in first-line patients with non-small cell lung cancer (NSCLC) with HER2 exon 20 mutations from cohort 4 of the ZENITH20 clinical trial at the upcoming European Society for Medical Oncology Congress (ESMO) 2021 that will take place virtually September 16-20, 2021.